866-997-4948(US-Canada Toll Free)

Axillary Hyperhidrosis - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 53 Pages

Axillary Hyperhidrosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2017, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 1 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Axillary Hyperhidrosis - Overview
Axillary Hyperhidrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axillary Hyperhidrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axillary Hyperhidrosis - Companies Involved in Therapeutics Development
Allergan Plc
Brickell Biotech Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittle
GlaxoSmithKline Plc
TheraVida Inc
Axillary Hyperhidrosis - Drug Profiles
(oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
botulinum toxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrronium tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sofpironium bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
umeclidinium bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Axillary Hyperhidrosis - Dormant Projects
Axillary Hyperhidrosis - Discontinued Products
Axillary Hyperhidrosis - Product Development Milestones
Featured News & Press Releases
Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting
Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting
Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting
Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference
Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
Oct 01, 2016: Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Sep 28, 2016: Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis
Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
Jan 07, 2016: Dermira Provides DRM04 Development Program Update
Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Axillary Hyperhidrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Axillary Hyperhidrosis - Pipeline by Allergan Plc, H1 2017
Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H1 2017
Axillary Hyperhidrosis - Pipeline by Dermira Inc, H1 2017
Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H1 2017
Axillary Hyperhidrosis - Pipeline by TheraVida Inc, H1 2017
Axillary Hyperhidrosis - Dormant Projects, H1 2017
Axillary Hyperhidrosis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Axillary Hyperhidrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *